Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients.
Accumulation of free radicals in the epidermis and the role of oxidative stress have been demonstrated in the pathogenesis of vitiligo. So, new treatment modalities that support antioxidant systems may be a choice for treatment. We sought to determine the clinical efficacy of narrow band ultraviolet B plus topical formulation including Cucumis melo superoxide dismutase and catalase (Vitix), over the narrow band ultraviolet B treatment alone. Thirty vitiligo patients (18 female, 12 male; mean age 34 +/- 13 years) were included in this study. 15 patients in Group 1 were treated only with narrow band ultraviolet B whereas 15 patients in Group 2 were treated with narrow band ultraviolet B plus topical Vitix for 6 months. Areas of 21 lesions from each group were measured by point counting methods at the beginning and at the end of the treatment. Efficacy of treatment was graded as perfect, good, moderate and poor according to healing percentages of measured areas and both groups were compared statistically. In Group 1 two moderate; in Group 2 one perfect, four moderate healings were observed at the end of the treatment. There was no statistically significant difference according to healing percentages between the two groups (p > 0.05). No adverse effect was reported in either group. The superiority of narrow band ultraviolet B plus topical Vitix treatment over narrow band ultraviolet B treatment could not be demonstrated statistically. There is a need for further studies involving large case series to clarify the results of our preliminary study.
Yuksel
Esra Pancar
EP
Ondokuz Mayis University, School of Medicine, Department of Dermatology, TR-55139 Kurupelit, Samsun, Turkey. esrapancar@yahoo.com
Aydin
Fatma
F
Senturk
Nilgun
N
Canturk
Tayyar
T
Turanli
Ahmet Yasar
AY
D000287:Administration, Topical; D000328:Adult; D002374:Catalase / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D018709:Statistics, Nonparametric; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*; D014820:Vitiligo / Q000188:drug therapy* / Q000532:radiotherapy*
D002374:Catalase; D013482:Superoxide Dismutase; C507649:Vitix